HealthQuill Articles by: HealthQuill
British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the disease or the patient dying by 56% compared to the usual treatment.
Drugs Health Pharma

AstraZeneca’s pill to treat breast cancer cuts disease worsening by 56%

HQ Team June 4, 2025: British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the

Read More
A third of patients with a type of blood cancer, especially those whose disease had returned or not responded to other treatments, have shown “promising” results in an early Johnson & Johnson trial.
Drugs Health Pharma

A third of blood cancer cases in J&J trials live without detectable cancer 

HQ Team June 4, 2025: A third of patients with a type of blood cancer, especially those whose disease had returned or not

Read More
Billionaire Elon Musk’s Neuralink has raised $650 million in Series E funding from key investors and its clinical trials for brain implant devices have started in three countries.
Drugs Health Pharma

Musk’s Neurolink raises $650 million, brain implant trials start in 3 countries

HQ Team June 3, 2025: Billionaire Elon Musk’s Neuralink has raised $650 million in Series E funding from key investors and its clinical

Read More
Definitive evidence has emerged from a global colon cancer trial that people who follow a structured exercise programme after surgery and chemotherapy have better odds of survival and lower risk of cancer coming back.
Drugs Health Research

Exercise helps colon cancer patients live longer, lowers recurrence rate

HQ Team June 3, 2025: Definitive evidence has emerged from a global colon cancer trial that people who follow a structured exercise programme

Read More
AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, has cut the risk of disease progression or death by 44% compared to a taxane, trastuzumab and pertuzumab combination. 
Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu cuts breast cancer progression by 44%

HQ Team June 3, 2025: AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, has cut the risk of disease progression or death by

Read More
The number of active Covid-19 cases in India approached the 4,000-mark, with 161 people being infected with the disease in southern Kerala state and 82 being reported from the capital, New Delhi, as of June 2. 
Drugs Health Pharma

India’s active Covid-19 cases nears 4,000-mark, 32 deaths since January

HQ Team June 3, 2025: The number of active Covid-19 cases in India approached the 4,000-mark, with 161 people infected with the disease

Read More
Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for a weight-loss drug candidate.
Drugs Health Pharma

Regeneron to pay China’s Hansoh $80m upfront for weight-loss drug

HQ Team June 2, 2025: Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for

Read More
US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation of an immunotherapy candidate to treat multiple tumour types.
Drugs Health Pharma

Bristol, BioNTech in $11.1b pact for immunotherapy candidate

HQ Team June 2, 2025: US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation

Read More
The World Health Organization has called on governments to ban all flavours in tobacco and nicotine products, including cigarettes, pouches, hookahs and e-cigarettes, to protect youth from addiction and disease.
Drugs Health Pharma

WHO urges governments to ban all tobacco flavours, nicotine products

HQ Team June 2, 2025: The World Health Organization has called on governments to ban all flavours in tobacco and nicotine products, including

Read More
France’s Sanofi SA will acquire US-based Blueprint Medicines Corporation for $9.1 billion to gain access to an immunology medicine for a rare disease and expand the company’s portfolio.
Drugs Health Pharma

Sanofi to acquire Blueprint for $9.1b for immunology medicine

HQ Team June 2, 2025: France’s Sanofi SA will acquire US-based Blueprint Medicines Corporation for $9.1 billion to gain access to an immunology

Read More